MLTX
MoonLake ImmunotherapeuticsNASDAQHealthcare$17.36+5.08%ClosedMarket Cap: $1.25B
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.68
P/S
0.00
EV/EBITDA
-4.49
DCF Value
$4.08
FCF Yield
-15.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.1%
ROA
-53.6%
ROIC
-64.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-62.4M | $-0.93 |
| FY 2025 | $0.00 | $-227.3M | $-3.53 |
| Q3 2025 | $0.00 | $-69.7M | $-1.10 |
| Q2 2025 | $0.00 | $-55.2M | $-0.87 |
Analyst Ratings
View AllBTIGBuy
2026-03-30Wolfe ResearchOutperform
2026-03-23Rothschild & CoBuy
2026-03-19Clear StreetBuy
2026-03-11RBC CapitalSector Perform
2026-03-02Trading Activity
Insider Trades
View AllBVF PARTNERS L P/ILdirector, 10 percent owner:
SellThu Apr 02
BVF PARTNERS L P/ILdirector, 10 percent owner:
SellThu Apr 02
BVF PARTNERS L P/ILdirector, 10 percent owner:
SellThu Apr 02
Bodenstedt Matthiasofficer: Chief Financial Officer
SellFri Jan 09
Santos da Silva Jorgedirector, officer: Chief Executive Officer
SellFri Jan 09
Company Info
Sector
Healthcare
Industry
—
Country
CH
Exchange
NASDAQ
Beta
1.19
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.